{"id":"F2020L00493","name":"Statement of Principles concerning malignant neoplasm of the liver (Reasonable Hypothesis) (No. 31 of 2020)","slug":"statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":440464,"registerId":"F2020L00493-fast-fetch-1775956072737","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning malignant neoplasm of the liver (Reasonable Hypothesis) (No. 31 of 2020)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nMALIGNANT NEOPLASM OF THE LIVER (Reasonable Hypothesis)\n\n(No. 31 of 2020)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 24 April 2020\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n| 
Professor Nicholas Saunders AO
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning malignant neoplasm of the liver (Reasonable Hypothesis) (No. 31 of 2020).\n\n2 Commencement\n\n This instrument commences on 25 May 2020.\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning malignant neoplasm of the liver No. 21 of 2011 (Federal Register of Legislation No. F2011L00500) made under subsections 196B(2) and (8) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about malignant neoplasm of the liver and death from malignant neoplasm of the liver.\n\nMeaning of malignant neoplasm of the liver\n\n(2) For the purposes of this Statement of Principles, malignant neoplasm of the liver:\n\n(a) means a primary malignant neoplasm arising from the hepatocytes; and\n\n(b) excludes:\n\n(i) carcinoid tumour;\n\n(ii) Hodgkin's lymphoma;\n\n(iii) malignant neoplasm of the bile duct;\n\n(iv) non-Hodgkin lymphoma; and\n\n(v) soft tissue sarcoma.\n\nNote: Malignant neoplasm of the liver is also known as hepatocellular carcinoma.\n\n(3) While malignant neoplasm of the liver attracts ICD‑10‑AM code C22.0, in applying this Statement of Principles the meaning of malignant neoplasm of the liver is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from malignant neoplasm of the liver\n\n(5) For the purposes of this Statement of Principles, malignant neoplasm of the liver, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the liver.\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that malignant neoplasm of the liver and death from malignant neoplasm of the liver can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the liver or death from malignant neoplasm of the liver with the circumstances of a person's relevant service:\n\n(1) having cirrhosis of the liver before the clinical onset of malignant neoplasm of the liver;\n\n(2) having chronic infection with hepatitis B virus before the clinical onset of malignant neoplasm of the liver;\n\nNote: chronic infection with hepatitis B virus is defined in the Schedule 1 - Dictionary. \n\n(3) having chronic infection with hepatitis C virus before the clinical onset of malignant neoplasm of the liver;\n\nNote 1: In the past, hepatitis C viral infection may have been classified as non-A, non-B hepatitis.\n\nNote 2: chronic infection with hepatitis C virus is defined in the Schedule 1 - Dictionary. \n\n(4) having chronic infection with hepatitis D virus before the clinical onset of malignant neoplasm of the liver;\n\nNote: chronic infection with hepatitis D virus is defined in the Schedule 1 - Dictionary. \n\n(5) having infection with human immunodeficiency virus before the clinical onset of malignant neoplasm of the liver;\n\n(6) having chronic hepatitis before the clinical onset of malignant neoplasm of the liver;\n\nNote: chronic hepatitis is defined in the Schedule 1 - Dictionary. \n\n(7) having diabetes mellitus for at least five years before the clinical onset of malignant neoplasm of the liver;\n\n(8) being overweight or obese for at least five years within the 20 years before the clinical onset of malignant neoplasm of the liver;\n\nNote: being overweight or obese is defined in the Schedule 1 - Dictionary. \n\n(9) for males, consuming at least 110 kilograms of alcohol within any ten year period at least five years before the clinical onset of malignant neoplasm of the liver;\n\nNote: Alcohol is measured by the alcohol consumption calculations utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.\n\n(10) for females, consuming at least 55 kilograms of alcohol within any ten year period at least five years before the clinical onset of malignant neoplasm of the liver;\n\nNote: Alcohol is measured by the alcohol consumption calculations utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.\n\n(11) smoking at least ten pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of malignant neoplasm of the liver, and:\n\n(a) smoking commenced at least five years before the clinical onset of malignant neoplasm of the liver; and\n\n(b) where smoking has ceased, the clinical onset of malignant neoplasm of the liver has occurred within 20 years of cessation;\n\nNote: pack-years of cigarettes, or the equivalent thereof in other tobacco products is defined in the Schedule 1 - Dictionary. \n\n(12) having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the liver at least five years before the clinical onset of malignant neoplasm of the liver;\n\nNote: cumulative equivalent dose is defined in the Schedule 1 - Dictionary. \n\n(13) being treated with systemic immunosuppressive therapy for solid organ, stem cell or bone marrow transplantation before the clinical onset of malignant neoplasm of the liver;\n\n(14) being exposed to high levels of dietary aflatoxins, on more days than not, for a period of at least five years within the 30 years before the clinical onset of malignant neoplasm of the liver;\n\nNote: being exposed to high levels of dietary aflatoxins is defined in the Schedule 1 - Dictionary. \n\n(15) inhaling a cumulative dose of at least 1 250 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of malignant neoplasm of the liver;\n\nNote: ppm-years is defined in the Schedule 1 - Dictionary. \n\n(16) inhaling gaseous vinyl chloride for a cumulative period of at least 5 000 hours while working in the production or processing of vinyl chloride monomer or polyvinyl chloride, at least five years before the clinical onset of malignant neoplasm of the liver;\n\n(17) inhaling respirable asbestos fibres in an enclosed space: \n\n(a) for a cumulative period of at least 1 000 hours before the clinical onset of malignant neoplasm of the liver; and\n\n(b) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and\n\n(c) where the first inhalation of respirable asbestos fibres commenced at least five years before the clinical onset of malignant neoplasm of the liver;\n\n(18) inhaling respirable asbestos fibres in an open environment:\n\n(a) for a cumulative period of at least 3 000 hours before the clinical onset of malignant neoplasm of the liver; and\n\n(b) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and\n\n(c) where the first inhalation of respirable asbestos fibres commenced at least five years before the clinical onset of malignant neoplasm of the liver;\n\n(19) an inability to undertake any physical activity greater than three METs for at least ten years within the 15 years before the clinical onset of malignant neoplasm of the liver;\n\nNote: MET is defined in the Schedule 1 - Dictionary.\n\n(20) using the combined oral contraceptive pill for a continuous period of at least three years before the clinical onset of malignant neoplasm of the liver, and where the use of the combined oral contraceptive pill has ceased, the clinical onset of malignant neoplasm of the liver has occurred within 30 years of cessation;\n\nNote: combined oral contraceptive pill is defined in the Schedule 1 - Dictionary. \n\n(21) taking or being treated with an anabolic-androgenic steroid:\n\n(a) for a continuous period of at least three years; and\n\n(b) to a cumulative total of at least 14 grams; and\n\n(c) where the cumulative total dose of anabolic-androgenic steroid was taken at least five years before the clinical onset of malignant neoplasm of the liver; and\n\n(d) where taking or being treated with the steroid has ceased, the clinical onset of malignant neoplasm of the liver has occurred within 20 years of cessation;\n\n(22) chewing betel quid or areca nut on more days than not, for at least five years before the clinical onset of malignant neoplasm of the liver, and where chewing of betel quid or areca nut has ceased, the clinical onset has occurred within 20 years of cessation;\n\n(23) being exposed to arsenic as specified before the clinical onset of malignant neoplasm of the liver, where the first exposure to arsenic occurred at least ten years before the clinical onset of malignant neoplasm of the liver;\n\nNote: being exposed to arsenic as specified is defined in the Schedule 1 - Dictionary. \n\n(24) having steatohepatitis for at least five years before the clinical onset of malignant neoplasm of the liver;\n\n(25) having autoimmune chronic active hepatitis or primary biliary cholangitis before the clinical onset of malignant neoplasm of the liver;\n\nNote: autoimmune chronic active hepatitis is defined in the Schedule 1 - Dictionary.\n\n(26) having a disorder from the specified list of disorders before the clinical onset of malignant neoplasm of the liver;\n\nNote: specified list of disorders is defined in the Schedule 1 - Dictionary.\n\n(27) inability to obtain appropriate clinical management for malignant neoplasm of the liver.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factor set out in subsection 9(27) applies only to material contribution to, or aggravation of, malignant neoplasm of the liver where the person's malignant neoplasm of the liver was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n autoimmune chronic active hepatitis means a chronic disorder of autoimmunity characterised by continuing hepatocellular necrosis and inflammation and seroimmunologic abnormalities.\n\n being exposed to arsenic as specified means:\n\n(a) consuming drinking water with an average arsenic concentration of at least 50 micrograms per litre for a cumulative period of at least ten years; or\n\n(b) consuming drinking water resulting in a cumulative total arsenic exposure equivalent to having consumed drinking water containing at least 50 micrograms per litre for at least ten years; or\n\n(c) having clinical evidence of chronic arsenic toxicity.\n\n being exposed to high levels of dietary aflatoxins means living or working in a geographic region or country where food items, particularly grains and nuts, are regularly contaminated with high levels of aflatoxins, and consuming these food items as a major part of the diet. \n\nNote: Geographic regions or countries where food items are regularly contaminated with high levels of aflatoxins include sub-Saharan Africa, Southeast Asia, Eastern Mediterranean and China.\n\n being overweight or obese means having a Body Mass Index (BMI) of 25 or greater.\n\nNote: BMI is also defined in the Schedule 1 - Dictionary.\n\n BMI means W/H2 where:\n\nW is the person's weight in kilograms; and\n\nH is the person's height in metres.\n\n chronic hepatitis means biochemical evidence of continuing or relapsing hepatocellular necrosis and hepatic inflammation for at least six months.\n\n chronic infection with hepatitis B virus means infection with hepatitis B virus resulting in a chronic infection of at least six months duration, and which must be confirmed by laboratory testing for hepatitis B serological or nucleic acid markers.\n\n chronic infection with hepatitis C virus means infection with hepatitis C virus resulting in a chronic infection of at least six months duration and which must be confirmed by laboratory testing for hepatitis C serological or nucleic acid markers.\n\n chronic infection with hepatitis D virus means infection with hepatitis D virus resulting in a chronic infection of at least six months duration and which must be confirmed by laboratory testing for hepatitis D serological or nucleic acid markers.\n\n combined oral contraceptive pill means contraceptive pills containing estrogen and progestogen.\n\n cumulative equivalent dose means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.\n\nNote 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.\n\nNote 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.\n\n malignant neoplasm of the liver—see subsection 7(2).\n\n MET means a unit of measurement of the level of physical exertion. 1 MET = 3.5 ml of oxygen/kg of body weight per minute, or 1.0 kcal/kg of body weight per hour, or resting metabolic rate.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n pack-years of cigarettes, or the equivalent thereof in other tobacco products means a calculation of consumption where one pack-year of cigarettes equals twenty tailor-made cigarettes per day for a period of one calendar year, or 7 300 cigarettes. One tailor-made cigarette approximates one gram of tobacco or one gram of cigar or pipe tobacco by weight. One pack-year of tailor-made cigarettes equates to 7.3 kilograms of smoking tobacco by weight. Tobacco products mean cigarettes, pipe tobacco or cigars, smoked alone or in any combination.\n\n ppm-years means parts per million multiplied by years of exposure.\n\n relevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n specified list of disorders means:\n\n(a) acute intermittent porphyria;\n\n(b) alpha-1 antitrypsin deficiency;\n\n(c) Budd-Chiari syndrome;\n\n(d) haemochromatosis;\n\n(e) porphyria cutanea tarda; or\n\n(f) Wilson's disease.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":false,"description":"This is a standard replacement Statement of Principles under the Veterans' Entitlements Act framework. It maintains the established scope of determining service-relatedness for specific medical conditions. While it updates medical evidence from the 2011 version (adding factors like steatohepatitis and refining exposure definitions), it does not expand beyond the original purpose of providing medical-scific criteria for compensation claims."},"complexity_factors":["27 distinct causal factors with varying temporal requirements (ranging from 5 to 30 years before clinical onset)","Multiple nested conditions within single factors (e.g., factor 11 has 3 sub-conditions; factors 17-18 have 3 cumulative requirements each)","19 defined terms in Schedule 1, many with their own mathematical formulas (BMI calculation, pack-years, ppm-years, cumulative equivalent dose)","Cross-references to external documents: ICD-10-AM Tenth Edition, Australian Radiation Protection and Nuclear Safety Agency methodology guide","Gender-specific thresholds (factors 9 and 10 for alcohol consumption)","Complex temporal relationships: 'within X years of cessation' clauses for smoking, contraceptives, steroids, and betel nut chewing","Reference to other Statements of Principles through section 11, creating interdependent legislative web","Specific quantitative thresholds requiring precise calculation (0.1 sievert radiation, 1,250 ppm-years vinyl chloride, 1,000 vs 3,000 hours asbestos depending on environment)"],"plain_english_summary":"This Statement of Principles sets the medical and scientific rules for deciding when hepatocellular carcinoma (liver cancer) can be accepted as related to Australian military service, replacing the 2011 version and listing 27 specific risk factors. \n\nIt affects veterans, peacekeepers, current and former defence members and their families claiming under veterans’ compensation laws — establishing evidence-based thresholds so service-linked risk factors can support entitlement to benefits."},"flash_summary":{"complexity_score":4,"scope_assessment":{"changed":true,"description":"This instrument expressly repeals and replaces the 2011 Statement of Principles for malignant neoplasm of the liver (section 4). Compared with a generic, earlier SoP model, the 2020 instrument modernises and expands the enumerated risk‑factor list and tightens technical definitions (see section 9 and Schedule 1). It adds or clarifies multiple metabolic/lifestyle and occupational exposures (for example, obesity/steatohepatitis, quantified alcohol thresholds, anabolic‑androgenic steroid dose limits, betel quid/areca nut, specific occupational exposure thresholds for vinyl chloride and asbestos, and updated definitions for radiation dose calculation). It also updates cross‑references (ICD‑10‑AM edition and dose calculation guidance). Those changes broaden and specify the medical criteria that can establish a reasonable hypothesis of service connection compared with a simple diagnostic statement, so the scope and application mechanics have materially changed from the earlier instrument."},"complexity_factors":["27 alternative factors listed in section 9 with many conditional requirements","Multiple technical measurement units and thresholds (pack‑years, ppm‑years, sieverts, BMI, METs, cumulative asbestos hours)","Substantial definitions in Schedule 1 (e.g., chronic infections require laboratory confirmation, cumulative equivalent dose with external guide reference)","Cross‑references to other Statements of Principles (section 11) and to external guidance (Guide to calculation of 'cumulative equivalent dose')","Temporal conditions and latency rules throughout (e.g. minimum durations, onset at least 5 or 10 years after exposure, post‑cessation time limits)","Repeal and replacement of a prior SoP (section 4) requiring reconciliation with earlier caselaw/assessments","Limited but consequential exceptions (explicit exclusions in section 7(2)(b))"],"plain_english_summary":"**What this instrument does (mechanically)**\n\n- This is a Statement of Principles (SoP) made by the Repatriation Medical Authority (RMA) under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (VEA). It replaces (repeals) the earlier 2011 SoP for malignant neoplasm of the liver (see section 4). It commenced on 25 May 2020 (section 2).\n\n- The instrument defines the medical condition covered: **malignant neoplasm of the liver** (primary cancer of hepatocytes, commonly called hepatocellular carcinoma) and death from that condition (section 7(2), (5)). It excludes certain other tumours and lymphomas (section 7(2)(b)).\n\n- It lists the medical, lifestyle and exposure **factors** such that, if at least one factor existed in a person and was related to their relevant service, a “reasonable hypothesis” can be raised that the condition is related to service (sections 8–10 and section 9). In other words, the presence of any one of the enumerated factors (together with the link to relevant service) is the minimum evidentiary threshold for considering the diagnosis to be service‑related for claims under the VEA or the MRCA (section 5).\n\n- The list contains 27 separate factors (section 9). They include: pre‑existing cirrhosis; chronic viral hepatitis (B, C, D); HIV infection; chronic hepatitis; long‑standing diabetes; obesity/overweight; quantified alcohol consumption; quantified tobacco use; measured ionising radiation dose to the liver; systemic immunosuppression after transplantation; long‑term dietary aflatoxin exposure; measured occupational exposures (vinyl chloride, asbestos, arsenic); prolonged physical inactivity (METs); use of combined oral contraceptives; anabolic‑androgenic steroid use (with dose and duration thresholds); betel quid/areca nut chewing; steatohepatitis; certain autoimmune or specified metabolic liver disorders; and inability to obtain appropriate clinical management (see section 9 and Schedule 1 definitions).\n\n- Many factors have technical thresholds and timing conditions (for example: minimum cumulative doses, minimum durations, latency periods of at least 5 or 10 years before clinical onset, and time limits after cessation for some exposures — see section 9 and Schedule 1). The instrument also cross‑refers to other SoPs when a listed factor is itself an injury/disease already covered by another SoP (section 11).\n\n**Who this affects**\n\n- Primary effect: veterans and former members of the Australian Defence Force (and members of Peacekeeping Forces or Forces covered under the MRCA) who lodge claims under the VEA or MRCA for primary liver cancer or death from it (section 5).\n\n- Secondary effects: medical practitioners and forensic/occupational clinicians who supply the clinical and exposure evidence to support claims; decision makers in the Department administering veterans’ entitlements who apply the SoP to individual claims; and, indirectly, employers or third parties where workplace exposures (e.g. asbestos, vinyl chloride, arsenic) are relied on as the relevant cause.\n\n**Why it matters (purpose claim and operational effect)**\n\n- The RMA states that there is sound medical‑scientific evidence that malignant neoplasm of the liver can be related to relevant service (section 8). The practical effect is to set an objective list of factors which, if present and related to service, meet the statutory threshold of a “reasonable hypothesis” that the condition is service‑related. That threshold governs whether entitlement claims proceed to a merits assessment for compensation/benefits under the VEA/MRCA.\n\n**Testing the purpose‑claim against costs, incentives and implementation trade‑offs**\n\n- Evidence burden and proof: many listed factors require objective clinical or laboratory confirmation (e.g. chronic viral infections confirmed by serology or nucleic acid testing; documented cumulative radiation dose; measured BMI; quantified alcohol/tobacco consumption). This shifts the evidentiary work onto claimants and their treating clinicians to produce historical, laboratory and exposure records (see section 9 and Schedule 1). Where exposures are occupational or remote in time, reconstructing them can be difficult and costly.\n\n- Administrative burden on decision makers: the Department will need to assess whether a listed factor existed and whether it was related to the person’s relevant service. For technical factors (ppm‑years, sieverts, cumulative asbestos hours) the Department may require specialist occupational hygiene or dose reconstruction input. That increases processing complexity and cost for adjudicators and may extend claim timelines.\n\n- Concentrated benefits, diffuse costs: the direct beneficiaries are claimants who can marshal evidence of any listed factor. The costs (administrative, medical documentation, and potential payments) are borne by the veterans’ compensation system and, indirectly, taxpayers. Where workplace exposures are relied upon, employers or liability schemes might face follow‑on claims outside this SoP, but the SoP itself governs veterans’ entitlements rather than employer liability.\n\n- Behavioural incentives: claimants and clinicians will tend to emphasise and document the listed factors in building claims (for example, ordering hepatitis serology, documenting alcohol/tobacco history, or obtaining occupational exposure histories). The SoP creates a predictable list of routes into a successful reasonable hypothesis finding, which reduces uncertainty about what evidence is material.\n\n- Risk of substitution and evidentiary gaps: some relevant causal pathways for liver cancer (for example, multifactorial metabolic disease) may involve combinations of weaker factors rather than a single dominant factor. The SoP requires at least one listed factor (section 9), which can both simplify adjudication and risk overlooking causation where no single enumerated factor is clearly present but the totality of risk is increased.\n\n- Bureaucratic discretion and cross‑reference risk: the RMA sets the medical criteria, but the determination whether the factor is “related to relevant service” (section 10) is an administrative decision; the SoP’s cross‑reference rule (section 11) requires decision makers to consult other SoPs when a factor overlaps another listed injury/disease, which adds layers of cross‑checking.\n\n**Key implementation details to watch**\n\n- Many factors carry technical thresholds (pack‑years, kg alcohol over time, sieverts, ppm‑years, cumulative asbestos hours, BMI, durations and latency requirements). These need precise evidence and, in some cases, specialist reconstruction (section 9; Schedule 1 definitions).\n\n- The instrument updates references (e.g. ICD‑10‑AM code and methodology for cumulative equivalent dose) and supplies definitions (Schedule 1) that control how the factors are applied in practice (sections 7(3)–(4); Schedule 1).\n\n**Who pays and who decides**\n\n- The RMA sets the medical rules; Departmental administrators and review bodies apply them to individual claims and decide on entitlement. Costs of evidence collection (tests, specialist reports) are generally borne by claimants or by public health providers; final compensation/benefit payments are funded through the veterans’ entitlements framework (VEA/MRCA).\n\n**Bottom line (mechanical effect)**\n\n- This SoP replaces the 2011 version and supplies a modernised, enumerated list of medical, lifestyle and exposure factors (with thresholds and timing rules) that, if present and linked to relevant service, raise a reasonable hypothesis that primary liver cancer or death from it is related to service. It therefore standardises the medical threshold used to admit such claims to merits assessment under the VEA and MRCA (sections 4–11)."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20","history":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20/history","analysis":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20/analysis","conflicts":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20/important-cases","documents":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-liver-reasonable-hypothesis-no-31-of-20/documents"}}